This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Griesinger, F. et al. Safety and efficacy of pralsetinib in RET fusion–positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial. Ann. Oncol. https://doi.org/10.1016/j.annonc.2022.08.002 (2022)
Subbiah, V. et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial. Nat. Med. https://doi.org/10.1038/s41591-022-01931-y (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Killock, D. ARROW: pralsetinib hits target across cancers. Nat Rev Clin Oncol 19, 615 (2022). https://doi.org/10.1038/s41571-022-00683-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-022-00683-5